About LBRX

Founded: 2015
Employees: 35
CEO: Heather Turner
WebsiteView website: lbpharma.us

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Recent LBRX News & Updates

Announcement • Apr 24

Lb Pharmaceuticals Announces Publication of Results from Phase 2 Nova-1 Trial of Lb-102 in Schizophrenia

LB Pharmaceuticals Inc. announced the publication in the Journal of the American Medical Association Psychiatry of its manuscript titled “Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizophrenia: A Phase 2 Randomized Clinical Trial.” LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders. The positive data from the NOVA-1 trial were first announced in early 2025. In this four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple domains of neuropsychiatric disease. LB-102 is currently being evaluated in the pivotal Phase 3 NOVA-2 trial in patients with acute schizophrenia. NOVA-2 is a double-blind placebo-controlled trial that is 6 weeks in duration and designed to enroll approximately 460 patients across 25 sites in the United States. Topline results from NOVA-2 are anticipated in the second half of 2027 and if positive, the Company expects to hold a pre-NDA meeting with FDA thereafter.

Recent updates

No updates

LB Pharmaceuticals Inc Stock Price

LBRX Share Price Performance

LBRX Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

LB Pharmaceuticals Inc Key Details

About LBRX

Recent LBRX News & Updates

LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans

LB Pharmaceuticals Inc, Annual General Meeting, Jun 03, 2026

Lb Pharmaceuticals Announces Publication of Results from Phase 2 Nova-1 Trial of Lb-102 in Schizophrenia

Recent updates

LB Pharmaceuticals Inc Competitors

Erasca

Veracyte

Twist Bioscience

Arcus Biosciences